12th Update on the Management of Genitourinary Malignancies
(Formerly named Urologic Oncology: Advances in Clinical Practice)

October 13-14, 2017
The University of Texas MD Anderson Cancer Center
Dan L. Duncan Building (CPB), Floor 8, Rooms 1-8
1155 Pressler Street
Houston, Texas
Focus

The 12th Update on the Management of Genitourinary Malignancies Conference will focus on the diagnosis, treatment, clinical advances, and controversies in localized and advanced cancers of the bladder, prostate and kidney.

Educational Objectives

After attending the conference, participants should be able to

- Access treatment and management options for patients with rare genitourinary malignancies and be able to better counsel patients on these options (Knowledge, Competence, Performance, Patient Outcomes);
- Implement and illustrate clinical advances in the treatment approach to localized, locally advanced and metastatic prostate cancer (Knowledge, Competence, Performance);
- Access the best treatment option for urothelial carcinoma and incorporate emerging and novel techniques to provide optimal patient care (Knowledge, Competence, Performance, Patient Outcomes);
- Incorporate neoadjuvant therapy in the management of renal cell carcinoma (Knowledge, Competence, Performance);
- Incorporate neoadjuvant therapy in the management of renal cell carcinoma (Knowledge, Competence, Performance).
Call for Abstracts

Abstracts will be selected for poster presentation at the conference. Please submit abstracts via e-mail to urologiccongology@mdanderson.org. The deadline for submission is August 25, 2017. Authors of selected abstracts will be notified via e-mail by September 30, 2017.

MD Anderson Organizing Committee

Conference Chairs
Christopher G. Wood, MD
Program Chairman
Professor and Vice Chairman
Urology

Nizar M. Tannir, MD
Program Co-Chairman
Professor and Vice Chairman
Genitourinary Medical Oncology

Brian F. Chapin, MD
Program Co-Chairman
Assistant Professor
Urology

Conference Committee
Ana Aparicio, MD
Associate Professor
Genitourinary Medical Oncology

John W. Davis, MD
Associate Professor
Urology

Colin P. Dinney, MD
Professor and Chairman
Urology

Jose A. Karam, MD
Associate Professor
Urology

Neema Navai, MD
Assistant Professor
Urology

Curtis A. Pettaway, MD
Professor
Urology

Arlene O. Siefker-Radtke, MD
Associate Professor
Genitourinary Medical Oncology

Carol Fourtunia
Administrative Coordinator
Urology

Constance C. Tierney, CMP
Manager
CME/Conference Management

Program

Friday, October 13, 2017

7:30 a.m.  Registration and Continental Breakfast

8:25 Welcome and Opening Remarks
Christopher G. Wood, MD
Nizar M. Tannir, MD
Brian F. Chapin, MD

Session I: Rare Genitourinary Cancers and Benign Urology in the Cancer Patient
Moderator: Curtis A. Pettaway, MD

8:30 Update on the Management of Advanced Testicular Cancer
Shi-Ming Tu, MD

9:00 Update on the Management of Adrenocortical Carcinoma
Amishi Y. Shah, MD

9:30 Update on the Management of Locally Advanced and Metastatic Penile Cancer
Curtis A. Pettaway, MD

10:00 Questions and Answers

10:10 Break

10:30 Treatment of Locally Advanced Upper Tract Transitional Cell Carcinoma: The Rationale for Neoadjuvant Chemotherapy
Surena F. Matin, MD

11:00 Urinary Diversion Options After Radical Cystectomy: Tips and Tricks
William J. Graber, MD
Dealing With Benign Urologic Issues in the Cancer Patient: The MD Anderson Experience
William J. Graber, MD
Noon Questions and Answers
12:10 p.m. Lunch (Provided)
1:05 The Andrew C. von Eschenbach Lectureship
Introduction: Colin P. Dinney, MD; Christopher G. Wood, MD; Nizar M. Tannir, MD; Brian F. Chapin, MD

Session II: Renal Cell Carcinoma
Moderator: Jose A. Karam, MD
1:35 AUA/ASCO/EAU/NCCN Guidelines for the Small Renal Mass: Which One Should We Adopt?
Mehrad Adibi, MD
1:55 When is a Biopsy Indicated for the Small Renal Mass in 2017?
Surena F. Matin, MD
2:15 Imaging for Renal Masses: What Should We Use in 2017?
Aradhana M. Venkatesan, MD
2:35 Ablative Therapy for the Small Renal Mass: An Update
Sharjeel H. Sabir, MD
2:55 Questions and Answers
3:00 Break
3:20 Adjuvant Therapy for Renal Cell Carcinoma in 2017: Ready for Primetime?
Jose A. Karam, MD
3:40 The Role of Lymphadenectomy for Renal Cell Carcinoma in 2017: Is It Necessary?
Jeffrey J. Tomaszewski, MD
4:00 Debate: Partial Nephrectomy for T1b Renal Tumors
Pro: Christopher G. Wood, MD
Con: Surena F. Matin, MD
4:30 What is the Standard of Care and Available Options in Front Line and Second Line Therapy and Beyond for Metastatic Renal Cell Carcinoma?
Eric Jonasch, MD
4:50 What is Available for Non-Clear Cell Histology Metastatic Renal Cell Carcinoma?
Nizar M. Tannir, MD
9:10  **NIMBC Case Discussions**  
**Moderator:** Ashish Kamat, MD  
**Panel:** Urologic Oncology Faculty

### Muscle Invasive Bladder Cancer and Upper Tract Disease
**Moderator:** Neema Navai, MD

**9:25**  
**Debate:** RPLND is Mandatory During Nephroureterectomy  
**Pro** Surena F. Matin, MD  
**Con** Jose A. Karam, MD

**9:40**  
Questions and Answers

**9:50**  
Break

**10:00**  
**Debate:** What is the Best Management for the Patient With cT2 Bladder Cancer Who Refuses Cystectomy?

- **Trimodal Therapy**  
  Seungtaek Choi, MD

- **Radical TURBT**  
  Ashish Kamat, MD

- **Partial Cystectomy With PLND**  
  Colin P. Dinney, MD

**10:20**  
**MIBC and Upper Tract Cases**  
**Moderator:** Neema Navai, MD  
**Panel:** Urologic Oncology, Radiation Oncology and Medical Oncology Faculty

### Locally Advanced and Metastatic Urothelial Carcinoma
**Moderator:** Arlene O. Siefker-Radtke, MD

**10:40**  
**Debate:** What is the Best Immunotherapy Regimen for Urothelial Cancer:

- **PD1 or PDL1 Inhibition**  
  Jianjun Gao, MD, PhD

- **Combination Therapy With Anti CTLA4 and PD1 or PDL1 Inhibition**  
  Arlene O. Siefker-Radtke, MD

**11:00**  
**Debate:** What is the Best Initial Systemic Therapy?

- **Immunotherapy**  
  Jianjun Gao, MD, PhD

11:20  
**Systemic Therapy in Localized Disease Case Discussions:**  
**Managing Toxicity**  
**Moderator:** Arlene O. Siefker-Radtke, MD  
**Panel:** Medical Oncology Faculty

**11:40**  
**The Changing Landscape of Systemic Therapy: New Agents and Novel Therapies**  
Arlene O. Siefker-Radtke, MD

**11:50**  
**Locally Advanced and Metastatic Urothelial Cancer Case Discussions**  
**Moderator:** Amishi Y. Shah, MD  
**Panel:** Urologic Oncology, Radiation Oncology, and Medical Oncology Faculty

12:10 p.m.  
Questions and Answers

12:15  
Lunch (Provided)

1:00  
**MACRA, MIPS and the Urologist: The Alphabet Soup of the Changing Healthcare Landscape and Why We Need to Know About It**  
Mehrad Adibi, MD

### Distinguished Alumni Lectures
**Moderator:** Brian F. Chapin, MD; Nizar Tannir, MD

**1:15**  
**David A. Swanson Distinguished Alumni Lecture Series**  
Peter Black, MD

**1:40**  
**Distinguished Genitourinary Medical Oncology Alumni Lecture**  
Avishay Sella, MD

### Session IV: Prostate Cancer
**Moderator:** Brian F. Chapin, MD

**2:00**  
**PSA Screening: A Reboot From the USPSTF**  
John W. Davis, MD

**2:15**  
**Critique, Questions, and Answers**  
Curtis A. Pettaway, MD

**2:20**  
**Challenging Cases in Prostate Biopsy Part 1**  
Leonard Gomella, MD

**2:35**  
**Challenging Cases in Prostate Biopsy Part 2**  
John W. Davis, MD
2:50 Surgery for Localized Disease: Impact on Survivor and Quality of Life
Louis L. Pisters, MD

3:00 Critique, Questions, and Answers
Steven J. Frank, MD

3:05 Break

3:10 Control of the Primary Tumor in the Setting of Metastatic Disease: Update on Clinical Trials and What To Do Now
Brian F. Chapin, MD

3:25 Critique, Questions, and Answers
Ana Aparicio, MD; Christopher J. Logothetis, MD

3:30 Radiation Therapy for Prostate Cancer Update: A Physicists Point of View
Rajat J. Kudchadker, PhD

3:45 Critique, Questions, and Answers
Steven J. Frank, MD

3:50 High Risk Prostate Cancer: The Neoadjuvant Therapy Narrative
Eleni Efstathiou, MD, PhD

4:05 Critique, Questions, and Answers
Ana Aparicio, MD; Christopher J. Logothetis, MD

4:10 Critique, Questions, and Answers
Brian F. Chapin, MD; John W. Davis, MD

4:15 Case Discussions
Moderator: Brian F. Chapin, MD
Panel: Mitchell S. Anscher, MD; Ana Aparicio, MD; John W. Davis, MD; Eleni Efstathiou, MD, PhD; Steven J. Frank, MD; Curtis A. Pettaway, MD; Louis L. Pisters, MD; John F. Ward, MD

4:35 Adjourn
The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

Registration Information

On-site registration opens at 7:30 a.m. on Friday, October 13, 2017. The conference will begin at 8:25 a.m. on Friday, October 13, 2017 and adjourn on Saturday, October 14, 2017 at 4:35 p.m. Advanced registration is encouraged as space and materials are limited. Please see the registration form for applicable fees.

The full conference registration fee includes the tuition, program, USB, continental breakfasts, breaks, lunches, and reception.

The deadline for advance registration is Friday, September 29, 2017.

There are three ways to register:
1. On-line at www.mdanderson.org/conferences
2. Fax to: 713-794-1724
3. Mail to: CME/Conference Management Unit 1781 The University of Texas MD Anderson Cancer Center P.O. Box 301407 Houston, TX 77230-1407.

We accept the following forms of payment:
1. Check (payable through U.S. banks only)
2. Money Order
3. Credit Cards (MasterCard, VISA, and American Express)
4. Cash (on-site registration only)

When registering online a receipt/confirmation letter will be automatically e-mailed to the e-mail address you list on the registration form. If you register by fax or mail, a receipt/confirmation letter will be sent to you within ten working days of receipt of your fee.

Refund/Cancellation Policy:

The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before September 29, 2017. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form. In case of activity cancellation, the liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

Guest Faculty

Scott Delacroix, MD
Urology
LSU Health
Metairie, Louisiana

Jeffrey J. Tomaszewski, MD
Assistant Professor
Surgery
Assistant Director
Genitourinary Oncology
MD Anderson Cancer Center at Cooper Camden, New Jersey

Andrew C. von Eschenbach Lecture Series

Leonard Gomella, MD
Chairman
Department of Urology
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

Distinguished Alums

David A. Swanson Distinguished Alumni Lecture Series
Urology Alumnus:

Peter Black, MD
Associate Professor
Department of Urologic Sciences
University of British Columbia
Vancouver, Canada

GU Medical Oncology Alumna:

Avishay Sella, MD
Head
Department of Oncology
Asaf Harofeh Medical Center
Zerifin, Israel
The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

Special Assistance
Contact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

Accommodations
- A block of rooms has been reserved for conference attendees at the Houston Marriott Medical Center, 6580 Fannin Street, Houston, Texas.
- Early hotel reservation is suggested. To make reservations, please call Reservations at 713-796-0080 and identify yourself as part of the MD Anderson Urologic Oncology Conference.
- The special meeting rate is $109.00 single or double occupancy. Please add 17% Texas State and local taxes. Reservations and deposits received after September 21, 2017 will be confirmed if space is available and at current hotel published guest room rates.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

Ground Transportation
(prices are subject to change and variable depending on location of conference)
- Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU).
- Taxicabs are available at an estimated cost for $50-60, to or from William P. Hobby Airport or George Bush Intercontinental Airport.
- Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Houston Marriott Medical Center for $27 one-way and $54 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or on-line at www.supershuttle.com.
- Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Houston Marriott Medical Center for $24 one-way and $48 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or on-line at www.supershuttle.com.

GENERAL CONFERENCE REGISTRATION FEES

<table>
<thead>
<tr>
<th>Physician/Scientist</th>
<th>Postmarked before September 29, 2017</th>
<th>$250.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postmarked after September 29, 2017</td>
<td>$300.00</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Students / Trainees / PAs / Advanced Nurse Practitioners</th>
<th>Postmarked before September 29, 2017</th>
<th>$100.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postmarked after September 29, 2017</td>
<td>$150.00</td>
<td></td>
</tr>
</tbody>
</table>

Please fill out the form below for registration:

- Last Name
- First Name
- Middle Initial
- Department (include unit no.)
- Institution
- MD Anderson Employee ID No. (required for all MDACC employees)
- Highest Degree
- Specialty
- Street
- City
- State/Foreign Country/Zip or Mail Code
- Daytime Phone (with area code)
- Cell Phone (with area code)
- Fax (with area code)
- E-mail Address (please print)
- Emergency Contact Phone (with area code)
- Charge the following:
  - VISA
  - MasterCard
  - American Express
- Credit Card Holder Name (First/Last)
- Credit Card Number
- Expiration Date
- MD Anderson Interdepartmental Transfer (IDT) No.
- Authorized Signature REQUIRED for credit card or IDT
- IDT Approver Name (First/Last)
- Business Unit
- Department
- Fund Group
- Fund
- Fund Type

Fund Group 90 will not be accepted.